Anteotech Ltd · ASX:ADO
Anteotech — Anteo Diagnostics — Shareholder Meeting (November 2010)
23 slides from Anteotech's shareholder meeting presentation, Nov 30, 2010
Slide 1: Annual General Meeting - Welcome
For personal use only ANTEO DIAGNOSTICS LTD (ASX:ADO) Annual General Meeting 30th November 2010 WELCOME
Slide 2: Meeting Format
MEETING FORMAT For personal use only • Introductions • Financial Accounts • Formal Resolutions • Other Business • Meeting Close • CEO Report
Slide 3: Introductions
For personal use only INTRODUCTIONS
Slide 4: Introductions
INTRODUCTIONS For personal use only Anteo Diagnostics Limited James Henderson – Non Executive Chairman Richard Martin – Non Executive Director Dr Geoff Cumming – CEO Lara Iacusso – Non Executive Director Dr Joe Maeji – Chief Scientific Officer Dr Nevin Abernethy – Chief Product Development and Resea
Slide 5: Financial Accounts
For personal use only FINANCIAL ACCOUNTS
Slide 6: Profit and Loss
PROFIT AND LOSS For personal use only Consolida te d 2010 2009 Note $ $ Sales revenue 2 84,271 226,312 Cost of sales - - Gross profit 84,271 226,312 Other revenue from ordinary activities 2 531,867 575,607 Selling and distribution expenses (486,775) (324,651) Occupancy expenses (33,000) (11,000) Adm
Slide 7: Balance Sheet
BALANCE SHEET Consolida te d For personal use only 2010 2009 Note $ $ CURRENT ASSETS Cash assets 8 1,425,894 953,354 Receivables 9 53,271 75,643 Other 10 1,939 1,541 TOTAL CURRENT ASSETS 1,481,104 1,030,538 NON-CURRENT ASSETS Property, plant and equipment 11 242,102 301,591 Intangible assets 12 - -
Slide 8: Cash Flow
CASH FLOW For personal use only Consolidated Note 2010 2009 $ $ Cash Flows from Operating Activities: Receipts from customers and government grants 549,510 734,141 Payments to suppliers and employees (2,743,019) (2,796,997) Borrowing costs (717) (568) Interest received 43,995 127,304 Net cash used i
Slide 9: Formal Resolutions
For personal use only FORMAL RESOLUTIONS
Slide 10: Resolutions
RESOLUTIONS For personal use only Resolution 1 – Adoption of Director’s Remuneration Report Resolution 2 – Re-Election of Director, Mr Richard Martin Resolution 3 – Re -Election of Director, Ms Laura Iacusso Resolution 4 – Issue of Options, Dr Geoffrey Cumming Resolution 5 – Resolution Withdrawn Res
Slide 11: Resolutions - Voting Results
RESOLUTIONS For personal use only Resolution For Against Open Abstain 1 Adoption of Remuneration 175,075,587 4,791,100 752,252 284,000 Report 2 Re-election of Mr Richard 178,644,337 1,221,250 757,252 280,100 Martin as a Director 3 Re-election of Ms Laura 168,111,004 11,421,250 757,252 613,433 Iacuss
Slide 12: Other Business and Question Time
For personal use only OTHER BUSINESS AND QUESTION TIME
Slide 13: Better Binding - Faster
For personal use only ANTEO DIAGNOSTICS LTD (ASX:ADO) Better Binding - Faster Geoff Cumming - CEO November 2010
Slide 14: Company Overview
Company Overview (ASX:ADO) For personal use only Anteo Diagnostics is a surface chemistry company whose patented technology is being widely assessed Strong Management Solid track record of developing commercially successful products Experienced Board with diverse skills Proven Technology Platform Pr
Slide 15: Business Model: Proprietary platform to build multiple pipeline and licensing opportunities
Business Model: Proprietary platform to build For personal use only multiple pipeline and licensing opportunities Proven technology platform; extensive pipeline and numerous deal opportunities Healthcare Research Bead manufacturers (eg Bangs, Merck, Seradyn, Dynal) Membrane manufacturers (eg Pall, M
Slide 16: Business Model: Proprietary platform to build multiple pipeline and licensing opportunities
Business Model: Proprietary platform to build multiple For personal use only pipeline and licensing opportunities Point of Care Membrane manufacturers (eg Pall, Millipore) Test manufacturers/suppliers (eg Future Diagnostics, Biosite) Molecular Diagnostics Instrument manufacturers (Qiagen, GE Healthc
Slide 17: Lead Product: Mix&Go
Lead Product: Mix&GoTM For personal use only • Result of screen on 8000 surfaces to find “glue” to bind antibodies to a solid surface • Successfully trialled by all major bead manufacturers and found to be faster, easier and less variable than current practice • Successfully trialled by most major I
Slide 18: Mix&Go Technology
Mix&GoTM Technology For personal use only Without Mix&GoTM Signal Signal Signal No Signal With Mix&GoTM Signal Signal Signal Signal Impact of Mix&GoTM: = detect disease earlier = more treatment options
Slide 19: Mix&Go Improves the Performance of a Bead Commonly Used in Diagnostic Immunoassays
Mix&GoTM Improves the Performance of a Bead Commonly Used in For personal use only Diagnostic Immunoassays Immunoassay Analyte IL-6# TSH TNFα α GM-CSF Bead B + 1.3 0.01 3.8 13 Mix&GoTM Bead B 10 0.06 37 1,000 # Limit of detection values in pg/ml, except TSH (µ µIU/ml)
Slide 20: Why Use Mix&Go
Why Use Mix&GoTM For personal use only • Lower cost to produce existing high volume tests • Improved performance of “difficult” tests • Lower cost and reduced time to market for new tests being developed • Ease of manufacture • Scalability RESULT: • Increased profits • Increased market share
Slide 21: Mix&Go: Commercialization Strategy
Mix&GoTM : Commercialization Strategy For personal use only • ADO has licensed Bangs Laboratories to use Mix&GoTM on “approved” Bangs manufactured beads. Revenues from sale of Mix&GoTM and royalty on sale of Mix&GoTM treated products • Signed Supply Agreement with Merck Chimie for Anteo to manufactu
Slide 22: What could Mix&Go be worth?
What could Mix&GoTM be worth? For personal use only • Research Market • $5-$10M • IVD Market • $30-$150M • POC Market • $50-$250M • Molecular Diagnostics • >$100M • Immunoprecipitation • >$100M Moderate success across these markets will significantly impact on ADO revenues and profits
Slide 23: Progress Over Past Months
Progress Over Past 12 Months For personal use only Companies assessing Mix&Go technology 2009 2010 Bead Manufacturers 5 10 IVD Companies/Assay Developers 5 14 POC Companies/Assay Developers 1 5 Molecular Diagnostics 2 4 Immunoprecipitation 1 11 Other - 3 TOTAL 14 47
Anteo Diagnostics — Shareholder Meeting (November 2010) on 6ix